Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Overview

USA - NASDAQ:CAMP - US13463J1016 - Common Stock

3.51 USD
-0.03 (-0.85%)
Last: 10/9/2025, 1:59:26 PM

CAMP Key Statistics, Chart & Performance

Key Statistics
52 Week High12.3
52 Week Low1.31
Market Cap70.76M
Shares20.16M
Float10.47M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-28.26
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-11 2024-10-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CAMP short term performance overview.The bars show the price performance of CAMP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

CAMP long term performance overview.The bars show the price performance of CAMP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CAMP is 3.51 USD. In the past month the price increased by 26.88%. In the past year, price decreased by -66.98%.

CAMP4 THERAPEUTICS CORP / CAMP Daily stock chart

CAMP Latest News, Press Relases and Analysis

CAMP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.86 408.89B
AMGN AMGEN INC 13.53 158.82B
GILD GILEAD SCIENCES INC 15.1 145.01B
VRTX VERTEX PHARMACEUTICALS INC 24.54 106.59B
REGN REGENERON PHARMACEUTICALS 12.46 60.29B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.69B
ARGX ARGENX SE - ADR 86.62 49.14B
ONC BEONE MEDICINES LTD-ADR 5.43 36.98B
INSM INSMED INC N/A 34.50B
BNTX BIONTECH SE-ADR N/A 25.25B
NTRA NATERA INC N/A 23.80B
BIIB BIOGEN INC 9.3 21.83B

About CAMP

Company Profile

CAMP logo image CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Company Info

CAMP4 THERAPEUTICS CORP

One Kendall Square, Bldg 1400 West 3rd Floor

Cambridge MASSACHUSETTS 92618 US

CEO: Jeffery Gardner

Employees: 644

CAMP Company Website

CAMP Investor Relations

Phone: 16176518867

CAMP4 THERAPEUTICS CORP / CAMP FAQ

What is the stock price of CAMP4 THERAPEUTICS CORP today?

The current stock price of CAMP is 3.51 USD. The price decreased by -0.85% in the last trading session.


What is the ticker symbol for CAMP4 THERAPEUTICS CORP stock?

The exchange symbol of CAMP4 THERAPEUTICS CORP is CAMP and it is listed on the Nasdaq exchange.


On which exchange is CAMP stock listed?

CAMP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CAMP4 THERAPEUTICS CORP stock?

11 analysts have analysed CAMP and the average price target is 9.18 USD. This implies a price increase of 161.54% is expected in the next year compared to the current price of 3.51. Check the CAMP4 THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CAMP4 THERAPEUTICS CORP worth?

CAMP4 THERAPEUTICS CORP (CAMP) has a market capitalization of 70.76M USD. This makes CAMP a Micro Cap stock.


How many employees does CAMP4 THERAPEUTICS CORP have?

CAMP4 THERAPEUTICS CORP (CAMP) currently has 644 employees.


What are the support and resistance levels for CAMP4 THERAPEUTICS CORP (CAMP) stock?

CAMP4 THERAPEUTICS CORP (CAMP) has a support level at 3.22. Check the full technical report for a detailed analysis of CAMP support and resistance levels.


Is CAMP4 THERAPEUTICS CORP (CAMP) expected to grow?

The Revenue of CAMP4 THERAPEUTICS CORP (CAMP) is expected to grow by 1925.02% in the next year. Check the estimates tab for more information on the CAMP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CAMP4 THERAPEUTICS CORP (CAMP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CAMP4 THERAPEUTICS CORP (CAMP) stock pay dividends?

CAMP does not pay a dividend.


What is the Price/Earnings (PE) ratio of CAMP4 THERAPEUTICS CORP (CAMP)?

CAMP4 THERAPEUTICS CORP (CAMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.26).


What is the Short Interest ratio of CAMP4 THERAPEUTICS CORP (CAMP) stock?

The outstanding short interest for CAMP4 THERAPEUTICS CORP (CAMP) is 4.48% of its float. Check the ownership tab for more information on the CAMP short interest.


CAMP Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to CAMP. When comparing the yearly performance of all stocks, CAMP is one of the better performing stocks in the market, outperforming 86.76% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CAMP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CAMP. The financial health of CAMP is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CAMP Financial Highlights

Over the last trailing twelve months CAMP reported a non-GAAP Earnings per Share(EPS) of -28.26. The EPS decreased by -2147.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -100%
ROE -127.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-169.57%
Sales Q2Q%-97.57%
EPS 1Y (TTM)-2147.83%
Revenue 1Y (TTM)-97.99%

CAMP Forecast & Estimates

11 analysts have analysed CAMP and the average price target is 9.18 USD. This implies a price increase of 161.54% is expected in the next year compared to the current price of 3.51.

For the next year, analysts expect an EPS growth of 67.98% and a revenue growth 1925.02% for CAMP


Analysts
Analysts85.45
Price Target9.18 (161.54%)
EPS Next Y67.98%
Revenue Next Year1925.02%

CAMP Ownership

Ownership
Inst Owners94.08%
Ins Owners3.47%
Short Float %4.48%
Short Ratio0.48